Abstract
Objective: High consumption of ω-3 polyunsaturated fatty acids (PUFAs) has been associated with lower plasma homocystine (Hcy) levels, but intervention studies in humans have been inconclusive. The objective was to systematically evaluate the effects of ω-3 PUFA supplementation on plasma Hcy levels. Methods: A comprehensive search of Medline, EMBASE, the Cochrane Clinical Trials Registry, and bibliographies of relevant articles published from 1966 through September 2010 was undertaken. All randomized, placebo-controlled trials that compared ω-3 PUFA supplementation with placebo were included. Two investigators performed data extraction and quality scoring independently, with discrepancies resolved by consensus. Results: Eleven trials including 702 subjects were analyzed. The outcomes studied were plasma Hcy level. Eleven randomized, placebo-controlled trials were included in this meta-analysis. Supplementation with ω-3 PUFAs was associated with a significant decrease in plasma Hcy level (weighted mean difference -1.59 μmol/L, 95% confidence interval -2.34 to -0.83) compared with control subjects. Conclusion: This meta-analysis suggested that ω-3 PUFA supplementation can decrease plasma Hcy levels. The implications of these findings remain to be elucidated.
| Original language | English |
|---|---|
| Pages (from-to) | 863-867 |
| Number of pages | 5 |
| Journal | Nutrition |
| Volume | 27 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 2011 |
Keywords
- ω-3 Polyunsaturated fatty acid
- Fish oil
- Homocysteine
- Meta-analysis
- Randomized, placebo-controlled trials
Cite this
}
High consumption of Ω-3 polyunsaturated fatty acids decrease plasma homocysteine : A meta-analysis of randomized, placebo-controlled trials. / Huang, Tao; Zheng, Jusheng; Chen, Ying; Yang, Bin; Wahlqvist, Mark L.; Li, Duo.
In: Nutrition, Vol. 27, No. 9, 09.2011, p. 863-867.Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - High consumption of Ω-3 polyunsaturated fatty acids decrease plasma homocysteine
T2 - A meta-analysis of randomized, placebo-controlled trials
AU - Huang, Tao
AU - Zheng, Jusheng
AU - Chen, Ying
AU - Yang, Bin
AU - Wahlqvist, Mark L.
AU - Li, Duo
PY - 2011/9
Y1 - 2011/9
N2 - Objective: High consumption of ω-3 polyunsaturated fatty acids (PUFAs) has been associated with lower plasma homocystine (Hcy) levels, but intervention studies in humans have been inconclusive. The objective was to systematically evaluate the effects of ω-3 PUFA supplementation on plasma Hcy levels. Methods: A comprehensive search of Medline, EMBASE, the Cochrane Clinical Trials Registry, and bibliographies of relevant articles published from 1966 through September 2010 was undertaken. All randomized, placebo-controlled trials that compared ω-3 PUFA supplementation with placebo were included. Two investigators performed data extraction and quality scoring independently, with discrepancies resolved by consensus. Results: Eleven trials including 702 subjects were analyzed. The outcomes studied were plasma Hcy level. Eleven randomized, placebo-controlled trials were included in this meta-analysis. Supplementation with ω-3 PUFAs was associated with a significant decrease in plasma Hcy level (weighted mean difference -1.59 μmol/L, 95% confidence interval -2.34 to -0.83) compared with control subjects. Conclusion: This meta-analysis suggested that ω-3 PUFA supplementation can decrease plasma Hcy levels. The implications of these findings remain to be elucidated.
AB - Objective: High consumption of ω-3 polyunsaturated fatty acids (PUFAs) has been associated with lower plasma homocystine (Hcy) levels, but intervention studies in humans have been inconclusive. The objective was to systematically evaluate the effects of ω-3 PUFA supplementation on plasma Hcy levels. Methods: A comprehensive search of Medline, EMBASE, the Cochrane Clinical Trials Registry, and bibliographies of relevant articles published from 1966 through September 2010 was undertaken. All randomized, placebo-controlled trials that compared ω-3 PUFA supplementation with placebo were included. Two investigators performed data extraction and quality scoring independently, with discrepancies resolved by consensus. Results: Eleven trials including 702 subjects were analyzed. The outcomes studied were plasma Hcy level. Eleven randomized, placebo-controlled trials were included in this meta-analysis. Supplementation with ω-3 PUFAs was associated with a significant decrease in plasma Hcy level (weighted mean difference -1.59 μmol/L, 95% confidence interval -2.34 to -0.83) compared with control subjects. Conclusion: This meta-analysis suggested that ω-3 PUFA supplementation can decrease plasma Hcy levels. The implications of these findings remain to be elucidated.
KW - ω-3 Polyunsaturated fatty acid
KW - Fish oil
KW - Homocysteine
KW - Meta-analysis
KW - Randomized, placebo-controlled trials
UR - http://www.scopus.com/inward/record.url?scp=79960947136&partnerID=8YFLogxK
U2 - 10.1016/j.nut.2010.12.011
DO - 10.1016/j.nut.2010.12.011
M3 - Review Article
VL - 27
SP - 863
EP - 867
JO - Nutrition
JF - Nutrition
SN - 0899-9007
IS - 9
ER -